Daniel Shevrin to Prostatic Neoplasms
This is a "connection" page, showing publications Daniel Shevrin has written about Prostatic Neoplasms.
Connection Strength
1.602
-
Genomic predictors for treatment of late stage prostate cancer. Asian J Androl. 2016 Jul-Aug; 18(4):586-91.
Score: 0.254
-
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19). J Clin Oncol. 2024 Apr 01; 42(10):1114-1123.
Score: 0.107
-
Brief assessment of priority symptoms in hormone refractory prostate cancer: the FACT Advanced Prostate Symptom Index (FAPSI). Health Qual Life Outcomes. 2003 Nov 21; 1:69.
Score: 0.106
-
Correlates of thrombin generation in patients with advanced prostate cancer. Thromb Haemost. 2003 Jan; 89(1):185-9.
Score: 0.100
-
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805. Prostate. 2022 09; 82(12):1176-1185.
Score: 0.095
-
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018 04 10; 36(11):1080-1087.
Score: 0.071
-
Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol. 2018 02 01; 36(4):376-382.
Score: 0.070
-
Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. Eur Urol. 2017 05; 71(5):740-747.
Score: 0.066
-
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015 Aug 20; 373(8):737-46.
Score: 0.060
-
The systemic delivery of an oncolytic adenovirus expressing decorin inhibits bone metastasis in a mouse model of human prostate cancer. Gene Ther. 2015 Mar; 22(3):247-56.
Score: 0.057
-
5a-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy. J Urol. 2015 Apr; 193(4):1388-93.
Score: 0.057
-
Phase II trial of echinomycin in advanced hormone-resistant prostate cancer. An Illinois Cancer Council study. Invest New Drugs. 1994; 12(1):65-6.
Score: 0.053
-
5a-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models. Endocrinology. 2013 Jul; 154(7):2296-307.
Score: 0.051
-
Ensuring comprehensive assessment of urinary problems in prostate cancer through patient-physician concordance. Urol Oncol. 2014 Jan; 32(1):26.e25-31.
Score: 0.051
-
A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):87-92.
Score: 0.046
-
Effect of etidronate disodium on the development of bone lesions in an animal model of bone metastasis using the human prostate cancer cell line PC-3. Prostate. 1991; 19(2):149-54.
Score: 0.043
-
Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice. Prostate. 2010 Oct 01; 70(14):1575-85.
Score: 0.043
-
Efficient assessment of the most important symptoms in advanced prostate cancer: the NCCN/FACT-P Symptom Index. Psychooncology. 2011 Sep; 20(9):977-83.
Score: 0.042
-
Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer. Value Health. 2010 Aug; 13(5):613-23.
Score: 0.041
-
Prolongation of off-cycle interval by finasteride is not associated with survival improvement in intermittent androgen deprivation therapy in LNCaP tumor model. Prostate. 2010 Feb 01; 70(2):147-54.
Score: 0.041
-
Patterns of metastasis by the human prostate cancer cell line PC-3 in athymic nude mice. Prostate. 1989; 15(2):187-94.
Score: 0.038
-
Development of skeletal metastasis by human prostate cancer in athymic nude mice. Clin Exp Metastasis. 1988 Sep-Oct; 6(5):401-9.
Score: 0.037
-
Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clin Cancer Res. 2008 Apr 15; 14(8):2437-43.
Score: 0.036
-
A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study. Cancer. 1993 Sep 15; 72(6):1965-8.
Score: 0.013
-
In vivo and in vitro approaches to study metastasis in human prostatic cancer. Cancer Metastasis Rev. 1993 Mar; 12(1):21-8.
Score: 0.013
-
Assessment of coagulation system activation using spot urine measurements. Blood Coagul Fibrinolysis. 1999 Jul; 10(5):285-9.
Score: 0.005
-
Use of clonidine to treat hot flashes secondary to leuprolide or goserelin. Ann Pharmacother. 1993 Feb; 27(2):182-5.
Score: 0.003
-
Analysis of gene amplification in human tumor cell lines. Proc Natl Acad Sci U S A. 1988 Sep; 85(18):6846-50.
Score: 0.002